Trajectories of health-related quality of life and fatigue during vedolizumab therapy in inflammatory bowel disease.

Casper SteenholdtRuben Due LorentsenPernille Nørgaard PetersenJørn Brynskov

Published in: Journal of gastroenterology and hepatology (2022)

QoL rapidly improves and predicts later significant clinical-objective efficacies of vedolizumab at end of induction and one year. Fatigue improves slowly after remission is attained.

Keyphrases

ulcerative colitis
patients with inflammatory bowel disease
sleep quality
depressive symptoms
disease activity
stem cells
rheumatoid arthritis
systemic lupus erythematosus
cell therapy
smoking cessation
bone marrow